Medical Facilities Corporation
TSX:DR.TOMedical - Care Facilities
+$0.18 today
- Market cap
- $282.59M
- Beta
- 0.34
- P/E (TTM)
- 8.7
- EPS (TTM)
- $1.47
- Dividend yield
- 2.00%
Volume 0.04M
Average 0.02M
DR.TO Net Income
Bottom-line profit after all expenses, interest, and taxes.
Medical Facilities CorporationTSX: DR.TO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $7.78M rose 108.6% year over year, ahead of the -65.6% change in trailing-twelve-month net income. Sequentially, it rose 42.9% from the prior quarter.
Context
- Net income amounted to 8.2% of revenue in FY2025, down 14.0 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of $41.16M (+95.2%) for the fiscal year ending Dec 2026, a step up from the -71.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $7.78M+42.9% QoQ
- Last fiscal yearDec 2025
- $21.08M-71.3% YoY
- LTMMar 2026
- $25.98M-65.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +108.6% | -26.6% | -135.2 pp |
| 1 year | -71.3% | +95.2% | +166.5 pp |
| 3-year CAGR | — | +19.0% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 21.08M USD
- Year-over-year change
- -71.3%
- 4-year CAGR
- +8.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.08M | -71.3% |
| FY2024 | 2024-12-31 | 73.49M | +297.2% |
| FY2023 | 2023-12-31 | 18.5M | +520.0% |
| FY2022 | 2022-12-31 | (4.41M) | -128.4% |
| FY2021 | 2021-12-31 | 15.5M | — |
Net Income vs competitors
How DR.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -65.6% is the 7th highest of 9, against a peer median of +16.4%.
- Net income amounts to 8.5% of revenue for DR.TO, versus a peer median of 20.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$33.21M CAD | +52.5% | — | 20.9% | |
| LTM Mar 2026 | CA$27.07M CAD | +820.5% | — | 7.2% | |
| LTM Mar 2026 | $25.98M USD | -65.6% | — | 8.5% | |
| LTM Mar 2026 | -$8.81M USD | +39.0% | — | 17.2% | |
| LTM Mar 2026 | -CA$25.21M CAD | -249.3% | — | 9.2% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | -$38.82M USD | -20.0% | — | 206.9% |
| LTM Mar 2026 | -$42.19M USD | -100.7% | — | — | |
| LTM Mar 2026 | -$81.53M USD | -6.2% | — | 31.2% | |
| LTM Mar 2026 | -CA$263.55M CAD | +55.9% | — | 84.8% | |
| Peer median (excluding DR.TO) | — | +16.4% | — | 20.9% | |
Competitors are the stored peer set for DR.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 398.63M | 424.55M | 445.58M | 331.53M | 258.62M |
| Cost of Revenue | 130.03M | 143.93M | 148.9M | 111.65M | 160.42M |
| Gross Profit | 268.61M | 280.63M | 296.68M | 219.88M | 98.2M |
| Gross Margin | 67.4% | 66.1% | 66.6% | 66.3% | 38.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 177.58M | 198.21M | 151.73M | 151.12M | 119.23M |
| Operating Expenses | 191.25M | 245.69M | 229.57M | 158.24M | 50.72M |
| Depreciation & Amortization | 26.77M | 20.76M | 21.54M | 19.37M | 11.94M |
| EBITDA | 103.4M | 51.15M | 72.43M | 82.57M | 59.41M |
| EBITDA Margin | 25.9% | 12.0% | 16.3% | 24.9% | 23.0% |
| Operating Income | 77.36M | 34.94M | 67.11M | 61.64M | 47.47M |
| Operating Margin | 19.4% | 8.2% | 15.1% | 18.6% | 18.4% |
| Interest Income | 76K | 8.54M | 717K | 1.87M | 2.24M |
| Interest Expense | 25.74M | 12.89M | 16.5M | 12.09M | 3.59M |
| Other Income / Expenses | (26.47M) | (17.44M) | (14.27M) | (10.53M) | (7.19M) |
| Income Before Tax | 50.89M | 17.5M | 52.32M | 51.11M | 40.28M |
| Pre-Tax Margin | 12.8% | 4.1% | 11.7% | 15.4% | 15.6% |
| Income Tax Expense | 4.4M | 5.21M | 8.33M | (5.69M) | 5.06M |
| Net Income | 15.5M | (4.41M) | 18.5M | 73.49M | 21.08M |
| Net Margin | 3.9% | -1.0% | 4.2% | 22.2% | 8.2% |
| EPS (Basic) | 1.50 | 0.42 | 0.73 | 1.03 | 1.09 |
| EPS (Diluted) | 1.49 | 0.42 | 0.73 | 1.03 | 1.09 |
| Weighted Avg Shares | 31.09M | 29.37M | 25.35M | 18.5M | 19.48M |
| Weighted Avg Shares (Diluted) | 31.13M | 29.37M | 25.25M | 24M | 19.48M |
Medical Facilities Corporation
TSX:DR.TO
Intrinsic Alpha fair value
Locked
Current Price
$17.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.